Management Team

Our management team is led by our Chief Executive Officer and co-founder, Bernard Gilly, who has been in the pharmaceutical sector for over 20 years, as an executive and an entrepreneur. He is supported by a management team with broad expertise in all aspects of turning science into solutions for patients.

Bernard Gilly
CEO and Co-Founder
Bernard Gilly
CEO and Co-Founder
Bernard Gilly, Ph.D., one of our founders, has served as our Chief Executive Officer since our creation. From our creation through to 2016, Bernard served as Chairman of our Board of Directors.

From 2011 through 2014, he served as Chief Executive Officer at Pixium Vision and from which date he has served as nonexecutive Chairman of the board of directors. In addition, he currently serves on the boards of Prophesee S.A. (formerly Chronocam) and Gecko Biomedical. From 2005 to 2009, he founded and was Chairman and Chief Executive Officer of Fovea Pharmaceuticals S.A., or Fovea, a privately funded biotech company, which was later acquired by Sanofi. He then became Senior Vice President of the Ophthalmology Division of Sanofi and served in that role until March 2012.

Prior to Fovea, Mr. Gilly was a partner at Sofinnova Partners S.A.S. from December 2000 to November 2005. From January 1992 to October 2000, he was Chief Executive Officer of Transgene S.A., a company listed on the Nasdaq and the Nouveau Marche of Euronext Paris, France. Mr. Gilly received an engineering degree from Ecole Nationale d’Agronomie and a Ph.D. from Universite de Rennes.
Thomas Gidoin
Chief Financial Officer
Thomas Gidoin
Chief Financial Officer
Thomas Gidoin has been our Chief Financial Officer since June 2015. From 2012 to mid-2015, Thomas was Vice President Finance at DBV Technologies S.A., where he led the Corporate Finance team and participated in public offerings and private placements, including the dual listing of DBV Technologies on the Nasdaq Global Select Market in 2014.

From 2008 to 2011, he served in various positions at Ipsen S.A.,
including UK Operations Controller in London and Senior Financial Analyst in the Global Operations division in Paris. He started his career in audit at Ernst & Young.

Thomas received a Master’s degree in International Finance from ESGF Paris and a Master’s degree in International Management from Neoma Business School in
France.
Barrett Katz
Chief Medical Officer
Barrett Katz
Chief Medical Officer
Barrett Katz, M.D., MBA, has served as our Chief Medical Officer since November 2017.

Prior to joining GenSight, Barrett was the Francis DeJur Chair of Ophthalmology at the Montefiore Medical Center and Albert Einstein College of Medicine in New York where he also served as Professor of Ophthalmology, Neurology and Neurosurgery, and the Executive Director of Clinical Trials from January 2010 to October 2017.

He has been engaged in the biotech industry and drug development space for many years, serving as Chief Executive Officer of Danube Pharmaceuticals Inc., Chief Medical Officer of Fovea, and Vice President for Medical Affairs and 153 Strategy at Eyetech Group Ltd. He studied at the National Hospital for Nervous Disease at Queen’s Square in
London, and served fellowships at Harvard and the University of California San Francisco. He interned in Internal Medicine at Parkland Hospital in Dallas, went to the National Institutes of Health in Neuro-Virology, completed a Neurology residency at Harvard Medical School and an Ophthalmology residency at Tufts-New England Medical Center.

Barrett received his M.D. from Case-Western Reserve University School of Medicine after graduating from Colgate University, and obtained an MBA from the University of Rochester’s Simon School of Business.
Julio Benedicto
Vice President, Marketing
Julio Benedicto
Vice President, Marketing
Julio Benedicto has been Vice President Marketing since November 2017.

He brings with him over 20 years’ experience as a strategy consultant, having helped clients in the life sciences industry develop and implement their brand and launch strategies in the US and Europe. Julio joined GenSight from the IMS Consulting Group (now IQVIA), where he was in the senior leadership team of the Munich office and a member of the global Launch Excellence team.

His expertise includes development and implementation of marketing and sales strategies, launch planning and execution, and buildup of commercialization processes and capabilities. His clients included not just the top pharmaceutical and biotechnology companies but also specialty firms, often focused on rare diseases, bringing their first product to market.

Julio graduated summa cum laude with a bachelor’s degree in economics from Yale and there also earned Master’s degrees in the same field.
Catherine Cancian
Vice President, Pharmaceutical Operations
Catherine Cancian
Vice President, Pharmaceutical Operations
Catherine Cancian has been our Vice President of Pharmaceutical Operations since April 2017, supporting our Pharmaceutical Development programs from preclinical to Phase III clinical studies and commercialization through strategic alliance management for manufacturing & supply operations.

Catherine has over 20 years’ experience in manufacturing operations and process improvement in biotechnology companies. She served at various positions at Sanofi Pasteur, including management level responsibilities in Manufacturing, Quality & CMC compliance, and project management, leading multifunctional project teams in the New Drug Application filing and marketing approval. From 2015 to 2017, she served at Genethon Bioproduction to lead industrialization projects for gene therapy vectors.

Catherine received a master’s degree in Neurosciences from Pierre & Marie Curie University (Paris), an Engineering Degree in Biotechnologies from UTC and a master’s degree in Business and Management of Strategic Units from HEC (Paris).
Harvey Masonson
Vice President, Clinical Development
M.D.
Harvey Masonson
Vice President, Clinical Development
M.D.
Harvey Masonson, M.D., joined GenSight in January 2018 in New Work.

Harvey is a Board-certified ophthalmologist with extensive and varied experience in the pharmaceutical industry in clinical research and clinical safety (Phases 1 to 4).

He is highly skilled at clinical development planning, protocol design, study conduct, analyses, reporting and publication of pre-registration and post-marketing trials. He has demonstrated success in clinical development programs culminating in NDA approval with a track record of production of clinical documents for FDA and EMDA submission from IND application/annual reports, NDA summaries (ISE/ISS/SCS) and safety updates.

Harvey’s experience also includes work on various preclinical, manufacturing, statistical, regulatory and marketing issues, with a strong background in utilization and management of CROs. He was a key manager at Eyetech, OSI as well as Ophthotech (SVP).

Harvey received his undergraduate degree from the University of Rochester, magna cum laude, and his M.D. from Mt. Sinai School of Medicine. He completed a residency in Ophthalmology at Mt. Sinai, and a fellowship in Glaucoma at New York Hospital, with additional post-graduate work at the NYU School of Business Administration.
Isabelle Pengue-Koyi
Vice President, Regulatory Affairs and Quality
Isabelle Pengue-Koyi
Vice President, Regulatory Affairs and Quality
Isabelle Pengue-Koyi, Pharm.D., Ph.D., has been Vice President Regulatory Affairs since September 2017.

After four years in R&D, Isabelle took up various positions in the Regulatory Affairs teams at Bristol Myers Squibb, Biogen Idec and Centelion before assuming the role of Associate Director Regulatory Affairs at IDM Biotech, where she managed a regulatory team and was responsible for developing the global regulatory strategies for Europe and USA, coordinating regulatory submissions, and leading interactions with regulatory agencies.

After serving as a consultant at Aptuit Consulting Ltd and as a free-lancer, she joined Institute Imagine of Genetic Disease in 2012 as a Regulatory Affairs Pharmacist, where she worked on the development of an advanced medicinal therapy product based on ex-vivo gene therapy product and on orphan genetic disease treatments.

Isabelle joined GenSight in 2014 as a Director of Regulatory Affairs and Quality Assurance. She holds a doctorate of Pharmacy (Pharm.D.) from PARIS XI University and a Ph.D. in pharmaco-chemistry at Institut Curie-Paris.
Isabelle Scarabin
Business Development Manager
Isabelle Scarabin
Business Development Manager
Isabelle Scarabin has been Business Development Manager at GenSight since September 2013.

She is responsible for the identification, assessment and management of business opportunities for potential collaboration/alliance/in- & out- licensing/M&A as well as public funding in support of GenSight’s corporate strategy.

Prior to GenSight, Isabelle had 10+ years of experience in several positions in non-profit organizations, and has wide experience consulting & supporting business development at biotech firms. She started her career in innovation management at Resources in Innovation and in new vaccine launch management and strategic marketing at Sanofi Pasteur MSD.

Isabelle received an Engineering Master’s degree in Biochemistry from the National Institute of Applied Sciences (INSA) Lyon and a Master’s degree in technology Management from emlyon Business School.

Board of Directors

Bernard Gilly is joined by seven directors in providing oversight over the company’s activities.

Michael Wyzga
Chairman
Michael Wyzga
Chairman
Michael Wyzga has served as a director since October 2013 and as our Chairman since March 2016. Mr. Wyzga is currently the President of MSW Consulting, Inc., a private company focused on strategic biotechnology consulting. Prior to that, Mr. Wyzga served as President and Chief Executive Officer and a member of the board of directors of Radius Health, Inc. (Nasdaq: RDUS), a biopharmaceutical company, from
December 2011 until November 2013.

Prior to that, Mr. Wyzga served in various senior management positions at Genzyme Corporation, a biopharmaceutical company, which was acquired by Sanofi in 2011. Mr. Wyzga joined Genzyme in February 1998 and most recently served as Executive Vice President, Finance from May 2003 until November 2011 and as Chief Financial Officer from July 1999 until November 2011.

Since February 2014, Mr. Wyzga has served as a member of the board of directors of Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company, where he is also a member of the compensation committee and chair of the audit committee. Since February 2013, Mr. Wyzga has also served as a member of the board of directors and chair of the audit committee of OncoMed Pharmaceuticals, Inc. (Nasdaq: OMED), a biopharmaceutical company.

Since February 2015, Mr. Wyzga has also served as a member of the board of directors of Exact Sciences Corporation (Nasdaq: EXAS), a medical technology company, where he is also a member of the audit and compensation committees.

Mr. Wyzga also previously served as a member of the board of directors of Idenix Pharmaceuticals, Inc., a publicly traded biotechnology company that was acquired by Merck in August 2014, where he also served as the chair of the audit committee and a member of the compensation committee, Altus Pharmaceuticals, Inc., a publicly traded biopharmaceutical company that ceased operations in November 2009, and as a member of the supervisory board of Prosensa Holding B.V., or Prosensa, a publicly traded biopharmaceutical company, from June 2014 until the Prosensa acquisition by BioMarin Falcon B.V. in December 2014. Mr. Wyzga received an MBA from Providence College and a B.S. from Suffolk University.
Bernard Gilly
CEO, Director and Co-Founder
Bernard Gilly
CEO, Director and Co-Founder
Bernard Gilly, Ph.D., one of our founders, has served as our Chief Executive Officer since our creation. From our creation through to 2016, Bernard served as Chairman of our Board of Directors.

From 2011 through 2014, he served as Chief Executive Officer at Pixium Vision and from which date he has served as nonexecutive Chairman of the board of directors. In addition, he currently serves on the boards of Prophesee S.A. (formerly Chronocam) and Gecko Biomedical. From 2005 to 2009, he founded and was Chairman and Chief Executive Officer of Fovea Pharmaceuticals S.A., or Fovea, a privately funded biotech company, which was later acquired by Sanofi. He then became Senior Vice President of the Ophthalmology Division of Sanofi and served in that role until March 2012.

Prior to Fovea, Mr. Gilly was a partner at Sofinnova Partners S.A.S. from December 2000 to November 2005. From January 1992 to October 2000, he was Chief Executive Officer of Transgene S.A., a company listed on the Nasdaq and the Nouveau Marche of Euronext Paris, France. Mr. Gilly received an engineering degree from Ecole Nationale d’Agronomie and a Ph.D. from Universite de Rennes.
Peter Goodfellow
Ph.D.
Peter Goodfellow
Ph.D.
Peter Goodfellow, Ph.D., has served as a director since June 2014. Dr. Goodfellow is a scientific consultant for Abingworth, Sanofi, and the Bill and Melinda Gates Foundation.

Dr. Goodfellow was previously the Balfour Professor of Genetics at Cambridge University before working for SmithKline Beecham (later GlaxoSmithKline) as head of research.

He has founded several biotechnology companies and has sat on the boards of Prosensa deCode and several medical charities. Dr. Goodfellow currently serves as the chairman of the board of directors of GammaDelta Therapeutics, a biotech developing novel immunotherapies for cancer and other diseases.

Dr. Goodfellow holds doctorates from Oxford and Bristol Universities.
Guido Magni
M.D., Ph.D.
Guido Magni
M.D., Ph.D.
Guido Magni, M.D., Ph.D., has served as a director since March 2013. Dr. Magni has been a Partner with Versant Ventures based in Basel, Switzerland.

Since 2012, Dr. Magni has served as a Managing Director of EuroVentures, a Versant incubator, where he was involved with several biotech investments including Synosia Therapeutics AG, which was sold to Biotie Therapeutics AG, Flexion Therapeutics Inc. and Okairos AG, which was sold to GlaxoSmithKline.

Dr. Magni was also the Chief Medical Officer of River Vision, which was sold to Horizon Pharma in 2017. Dr. Magni was previously the Global Head of Medical Sciences of Roche Pharmaceuticals, in the Global Drug Development department. During his 12 years in this position, Dr. Magni oversaw the development and the registration of a large number of new chemical and biological entities including
Pegasys, Mabthera, Xeloda, Herceptin, Tamiflu and Tarceva.

Dr. Magni currently serves on the boards of Aprea AB, Nouscom GmbH, Piqur Therapeutics AG, Tarveda LavaTherapeutics and AM Pharma B.V. Dr. Magni holds an M.D. and a Ph.D. in neuropharmacology from the University of Padua in Italy.
Simone Seiter
M.D., Ph.D.
Simone Seiter
M.D., Ph.D.
Simone Seiter, M.D., Ph.D., has served as a director since April 2017. Dr. Seiter is a Vice President with IQVIA (formerly QuintilesIMS) based in Frankfurt, Germany and has held the role for 12 years.

Prior to joining QuintilesIMS, Dr. Seiter worked at Capgemini as a consultant for six years and served as a postdoctoral Fellow at the National Institutes of Health (United States) for two years. Previously, Dr. Seiter worked at the Universities of Heidelberg and Homburg, Germany as board-certified dermatologist.

Dr. Seiter holds an M.D.-Ph.D. degree from the University of Heidelberg and an MBA from the University of Applied Sciences in Neu-Ulm Germany.
Natalie Mount
Ph.D.
Natalie Mount
Ph.D.
Natalie Mount, Ph.D., has served as a director since May 2017. Dr. Mount is currently Chief Scientific Officer, leading Research and Development activities, at GammaDelta Therapeutics.

Previously, she was Chief Clinical Officer at the Cell and Gene Therapy Catapult, where she was responsible for the translational, regulatory and clinical development activities for a wide range of cell and gene therapies.

Prior to that, Dr. Mount spent 16 years at Pfizer leading development activities across various therapeutic areas, including cell based therapies in the Regenerative Medicine Unit. Dr. Mount has also sat on the boards of directors of the Cell and Gene Therapy Catapult, CTTCR and Chimeric Therapeutics.

Dr. Mount has a first class degree in Natural Sciences from the University of Cambridge and a Ph.D. from University College, London.
Charlotte Corbaz
Representing Bpifrance Participations
Charlotte Corbaz
Representing Bpifrance Participations
Charlotte Corbaz has served as the representative of Bpifrance Participations on our board of directors since December 2017.

Ms. Corbaz has worked in the Large Venture Fund of Bpifrance Participations since the creation of the fund in 2013, and she currently serves as Investment Principal of the fund.

In 2011, Ms. Corbaz began her career in the Valuation and Modeling Department of Eight Advisory, and in 2012 she joined Fond Stratégique d’Investissement as an analyst.

Ms. Corbaz previously sat on the board of directors of VI Technology SAS and currently serves on the board of directors of Ekinops SA. She has a degree in Management from Audencia
Nantes.
Laurent Higueret
Observer
Laurent Higueret
Observer
Thibaut Roulon
Observer
Thibaut Roulon
Observer
Prof. Jose-Alain Sahel
Observer
M.D., Ph. D.
Prof. Jose-Alain Sahel
Observer
M.D., Ph. D.
Pr. Sahel is chairing the Vision Institute in Paris, a center of excellence in ophthalmology assembling scientific teams (University PM Curie, INSERM, CNRS) as well as the French National Eye, featuring access to cohorts of well-diagnosed patients and a state-of-the-art Clinical Investigation Center.

Scientific Advisory Board

Leading researchers and clinicians provide guidance on our research and development efforts.

Dr. Botond Roska
Chairman
Dr. Botond Roska
Chairman
Botond Roska is senior group leader at the Friedrich Miescher Institute in Basel Switzerland. He was educated at University of California Berkeley, Harvard University and Harvard Medical School as well as at Semmelweis Medical School. His group studies the structure and function of the retina. His group pioneered retina cell type specific optogenetic vision restoration.
Prof. Jose-Alain Sahel
Vice-Chairman
M.D., Ph. D.
Prof. Jose-Alain Sahel
Vice-Chairman
M.D., Ph. D.
Pr. Sahel is chairing the Vision Institute in Paris, a center of excellence in ophthalmology assembling scientific teams (University PM Curie, INSERM, CNRS) as well as the French National Eye, featuring access to cohorts of well-diagnosed patients and a state-of-the-art Clinical Investigation Center.
Prof. Jean Bennett
Vice-Chairman
M.D., Ph. D.
Prof. Jean Bennett
Vice-Chairman
M.D., Ph. D.
Jean Bennett is Professor of Ophthalmology and Cell and Developmental Biology and a Senior Investigator in the F. M. Kirby Center for Molecular Ophthalmology at the University Of Pennsylvania School Of Medicine. Jean also has an appointment as a Senior Investigator at the Center for Cellular and Molecular Therapeutics, The Children’s Hospital of Philadelphia (CHOP).
Prof. Ernst Bamberg
Prof. Ernst Bamberg
Ernst Bamberg is Professor of Biophysical Chemistry at University of Frankfurt, and Director of the Department of Biophysical Chemistry of the Max Planck Institute für Biophysik in Frankfurt. He is the inventor of the optogenetics approach and has been at the fore front of this technology since its discovery.
Prof. Connie Cepko
Prof. Connie Cepko
Connie Cepko is Professor at Harvard Medical School. She is working on the mechanisms that direct development of the central nervous system (CNS) of vertebrates, and particularly on the vertebrate retina. Connie has produced seminal works in the mechanisms that lead to the death of photoreceptors in the many inherited forms of human blindness.
Dr. Serge Picaud
Ph. D.
Dr. Serge Picaud
Ph. D.
Serge Picaud is director of research at the Vision Institute in Paris. Over the last 15 years, he has developed many cellular and animal models of different retinal diseases for assessing the efficacy of neuroprotection or other therapeutic strategies. He thus developed the culture of post-mortem human retinal tissue, which provides the means to test AAV vectors efficacy on human retinal neurones.
Luk H. Vandenberghe
Ph. D.
Luk H. Vandenberghe
Ph. D.
Luk Vandenberghe is Assistant Professor at Harvard Medical School and runs an active research laboratory at the Massachusetts Eye and Ear Infirmary and the Schepens Eye Research Institute. He directs the Grousbeck Gene Therapy Center which is focused on the biology of somatic gene transfer, the development of enabling technologies in gene therapy, and the translation of clinical programs with a particular emphasis on vision and hearing restoration.

Scientific Founders

We have taken the insights of our original scientific founders and built GenSight into the company it is today.

Prof. Jean Bennett
M. D., Ph. D.
Prof. Jean Bennett
M. D., Ph. D.
Jean Bennett, M.D., Ph.D., tenured professor of Ophthalmology and Cell and Developmental Biology, and vice chairman for research in Ophthalmology at the University of Pennsylvania (Penn) School of Medicine, is a pioneer in retinal gene therapy and internationally recognized for her work in this field.

She has developed gene transfer approaches to test treatment strategies for retinal degenerative and ocular neovascular diseases, to elucidate retinal differentiation pathways and to identify pathogenetic mechanisms that lead to blindness. In addition, her laboratory has developed gene transfer approaches to treat syndromic diseases resulting in vision loss, studies the immune response of the eye to viral vectors, and characterizes and utilizes cell specific promoters for the delivery of therapeutic nucleic acids.

Recently she was named the F.M. Kirby Professor of Molecular Ophthalmology. Her research, conducted at Penn over the past 16 years, has established the scientific underpinnings which made it possible to test the first potential definitive retinal gene therapy treatment for patients with blinding retinal degenerations.

Dr. Bennett is the principal investigator of the Foundation Fighting Blindness-funded The Children’s Hospital of Philadelphia (CHOP)-Penn Pediatric Center for Retinal Degenerations and the Scientific Advisor of a clinical trial that evaluates the safety and efficacy of gene augmentation for a Leber Congenital Amaurosis. This study was initiated in the fall of 2007 at The Children’s Hospital of Philadelphia.
Connie Cepko
Ph. D.
Connie Cepko
Ph. D.
Connie Cepko is Professor at Harvard Medical School. She is working on the mechanisms that direct development of the central nervous system (CNS) of vertebrates, and particularly on the vertebrate retina. Connie has produced seminal works in the mechanisms that lead to the death of photoreceptors in the many inherited forms of human blindness.
Dr. Serge Picaud
Ph. D.
Dr. Serge Picaud
Ph. D.
Serge Picaud is director of research at the Vision Institute in Paris.

Over the last 15 years, he has developed many cellular and animal models of different retinal diseases for assessing the efficacy of neuroprotection or other therapeutic strategies. He thus developed the culture of post-mortem human retinal tissue, which provides the means to test AAV vectors efficacy on human retinal neurones. He has also characterized many animal models using a phenotyping platform inspired from the clinical trial center.

He was a founder and advisor of the biotech company Fovea, which was bought by Sanofi-Aventis to become its ophthalmological division.
Jose-Alain Sahel
M. D., Ph. D.
Jose-Alain Sahel
M. D., Ph. D.
Jose-Alain Sahel is Professor at Université Pierre et Marie Curie, and Director of Institut de la Vision and Chairman of the Department of Ophthalmology at the Quinze-Vingts National Eye Hospital and at the Rothschild Ophthalmology Foundation in Paris, France. He is also Professor at the Institute of Ophthalmology at the University College in London.

He has been conducting pioneering research into the understanding of the pathological mechanisms involved in retinal cell degeneration.

Prof. Sahel recently received awards from the US Foundation Fighting Blindness and the French “Académie des Sciences”, for his work on retinitis pigmentosa.
Botond Roska
M. D., Ph. D.
Botond Roska
M. D., Ph. D.
Botond Roska is a senior group leader at the Friedrich Miescher Institute in Basel Switzerland. He was educated at University of California Berkeley, Harvard University and Harvard Medical School as well as at Semmelweis Medical School.

His group studies the structure and function of the retina. His group pioneered retina cell type specific optogenetic vision restoration (Lagali et al., Nature Neuro. 2008, Busskamp et al, Science, 2010). He received several international prizes and awards: EMBO member (2011) Alcon Award (2011) VIVA Award (2010) ERC Starting Investigator (2010) EMBO Young Investigator (2009) Marie Curie Excellence Grant (2006) HFSP Young Investigator (2003) Harvard Society Fellow (2002) HFSP Short Term Fellow (2001) Bearden Memorial Award for biophysics (2001) Fulbright Fellow (1997).
Luk H. Vandenberghe
M. D., Ph. D.
Luk H. Vandenberghe
M. D., Ph. D.
Luk Vandenberghe is Assistant Professor at Harvard Medical School and runs an active research laboratory at the Massachusetts Eye and Ear Infirmary and the Schepens Eye Research Institute.

He directs the Grousbeck Gene Therapy Center which is focused on the biology of somatic gene transfer, the development of enabling technologies in gene therapy, and the translation of clinical programs with a particular emphasis on vision and hearing restoration.

He is an Associate Director of the Ocular Genomics Institute, a collaborative venture within the Harvard Medical School Department of Ophthalmology, with the ambition to provide diagnosis, treatment, and advancement of the science of the genetic basis of blinding disorders.

Dr. Vandenberghe trained at the Katholieke Universiteit Leuven, Belgium in biological engineering and biomedical sciences. At the University of Pennsylvania, PA, USA he was a scholar and researcher in several premier translational gene therapy laboratories there. He discovered, developed and characterized some of the most widely used gene therapy carriers for in vivo and ex vivo applications including AAV, adeno- and lentiviral-based vectors.

Dr. Vandenberghe made groundbreaking contributions to better understand immune responses to AAV vectors and the targeting of cell types in the macula and retina important for genetic therapies for blindness. In his active career, he published over 40 peer reviewed articles and reviews. He is co-inventor on over a dozen published or pending patents including novel serotypes and improved manufacturing technologies of AAV.